CYRX Q3 FY2026 earnings: results, stock reaction and implied move

Reported results

Total revenue for Q3 2026 was $50.2 million, up 14% year-over-year compared to $44.2 million for Q3 2025.
GAAP loss from continuing operations was $10.9 million for Q3 2026, compared to a loss of $6.7 million for Q3 2025.
GAAP net loss attributable to common stockholders for Q3 2026 was $12.9 million, or $0.25 per basic and diluted share.
Non-GAAP adjusted EBITDA from continuing operations was $1.1 million for Q3 2026, compared to negative $0.6 million for Q3 2025.
Total gross margin was 47.5% for Q3 2026, compared to 48.2% for Q3 2025.
Life Sciences Services revenue for Q3 2026 was $28.6 million, up 18% year-over-year compared to $24.3 million for Q3 2025.

The Company updated full-year 2026 revenue guidance to a range of $197 million to $199 million.

Results for the CRYOPDP specialty courier business, divested on June 11, 2025, are presented as discontinued operations for all periods.

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.